Health

STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 27/10/2026, 06:36:26 UTC.

Briefings

Incyte reported that its targeted drug STAT+ combined with chemotherapy produced lasting tumor responses in some pancreatic cancer patients, justifying a move to a late-stage clinical trial. This finding builds on the earlier approval of Rasonque, which extended survival for patients with RAS mutations. The company is developing next-generation RAS-targeted therapies to achieve better outcomes. Evidence is limited to the biotech's internal statement at an ESMO conference.

Key points

• Incyte's drug STAT+ combined with chemotherapy induced lasting tumor responses in certain pancreatic cancer patients, supporting advancement to a late-stage clinical trial.
• The approval of Rasonque previously demonstrated that targeting RAS mutations can prolong survival in patients with aggressive pancreatic cancer.

Context

Incyte is advancing STAT+ into a late-stage clinical trial following its positive results. This follows the earlier approval of Rasonque, which showed survival benefits for patients with RAS mutations. The company is developing next-generation RAS-targeted therapies to improve results for patients with pancreatic cancer.

Limitations

Evidence is limited to Incyte's internal statement at an ESMO conference. No patient data, specific survival numbers, or independent validation studies are provided in the source.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 27/10/2026, 07:50:19 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeid7vhuqqkt45ybnbsyicw7ejmxda7dpcuqomnc7nmly7hukzhe2wi